Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index; 19 of the 41 sources its claims cite were checked for support.

PU.1 dictates β-amyloid-induced TREM2 expression upregulation in microglia in a transgenic model of Alzheimer’s disease

Open access
Wei, Zhen, Pan, Xiaodong, Cui, Xiaoli, Zhang, Jing, Dai, Xiaoman, Zeng, Yuqi, Chen, Xiaochun · 2025 · Frontiers in Aging Neuroscience

Abstract

Microglial dysfunction is characteristic of Alzheimer’s disease (AD), with triggering receptor expressed on myeloid cells 2 (TREM2) and transcription factor PU.1 playing crucial roles. However, the relationship between TREM2 and PU.1 remains unclear. We investigated TREM2 and PU.1 expression patterns in the 5×FAD mouse AD model. Experimental approaches included quantitative qPCR, western blotting, immunofluorescence staining, chromatin immunoprecipitation, and luciferase reporter assays to examine the interaction between PU.1 and TREM2. The phagocytic function of microglial cells was evaluated using Aβ42 and Nile red fluorescent microsphere phagocytosis assays. TREM2 and PU.1 expression significantly correlated with brain β-amyloid (β) deposition. PU.1 directly interacted with the TREM2 promoter region, promoting its transcription and potently impacting microglial phagocytosis. PU.1 overexpression amplified TREM2 expression, while PU.1 knockdown reduced it. Our findings reveal a novel regulatory mechanism where PU.1 directly modulates TREM2 transcription in activated microglia during AD progression.

Overview

CoChat Summary

## TL;DR

In 5×FAD Alzheimer’s mice and microglia models, the paper argues that PU.1/Spi1 drives β-amyloid-induced TREM2 upregulation by binding TREM2 regulatory regions and boosting transcription. This PU.1–TREM2 axis was linked to microglial phagocytosis, with knockdown of either gene reducing uptake of Aβ/fibrillar particles.

## Key findings

  • In 5×FAD mice, both TREM2 and PU.1 mRNA/protein levels were higher than in age-matched wild-type mice, and both increased with age; TREM2 showed no notable mRNA difference at 1 month of age, but was markedly elevated in aged mice (≥11 months).
  • Double immunofluorescence showed nearly all TREM2-positive microglia were PU.1-positive and vice versa, and Pearson analysis found a robust positive correlation between TREM2 and PU.1 in 5×FAD mice.
  • In BV2 microglia and primary microglia, oligomeric and fibrillar Aβ increased TREM2 expression in a time-dependent manner, with TREM2 becoming significant at 24 h after stimulation; PU.1 also rose, peaking at 12 h.
  • PU.1 knockdown reduced TREM2 mRNA/protein, PU.1 overexpression increased TREM2, and ChIP-qPCR plus luciferase assays supported direct binding/activation of the TREM2 promoter; one assay showed about a 5-fold increase in luciferase activity with PU.1 coexpression.
  • Functionally, TREM2 shRNA and PU.1 shRNA reduced Aβ42 uptake by approximately 55% and 50%, and reduced Nile red microsphere phagocytosis efficiency by approximately 33% and 30%, respectively.

## Methods

  • Used male 5×FAD APP/PS1 double transgenic mice and age-matched wild-type controls; analyzed hippocampal/brain tissues and isolated primary microglia, alongside BV2 mouse microglial cells.
  • Measured gene/protein expression and localization with qRT-PCR, western blotting, immunohistochemistry, and immunofluorescence; tested PU.1–TREM2 interaction with ChIP-qPCR and luciferase reporter assays.
  • Assessed function with Aβ42 and Nile red fluorescent microsphere phagocytosis assays; statistics used one-way or two-way ANOVA with Bonferroni correction and Pearson correlation.

## Limitations

  • The paper states it did not examine other transcription factors that may contribute to Aβ-mediated TREM2 expression.
  • The authors note that siRNA/shRNA knockdown does not equal complete PU.1 genetic deletion, and they say a floxed PU.1 mouse model and conditional knockout studies would be better for in vivo validation.
  • The paper says it relied heavily on BV2 cells for mechanistic work; it also notes BV2 cells do not fully recapitulate primary microglial gene expression/epigenetic features, and that future in vivo studies are needed.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fnagi.2025.1537388

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 Elevated TREM2 protein and mRNA levels in activated microglia in the hippocampus of 5 × FAD mice during disease progression. (A) Analysis of the mRNA expression of TREM2 in the hippocampi of 1 month-old to 18–20 months-old 5 × FAD mice and aged-matched WT mice. The expression of TREM2 mRNA is presented as the mean ± S.E.M. and is shown as the relative expression level according to the 2Δ Δ Ct method. The data were analyzed via one-way analysis of variance followed by Bonferroni post hoc correction. #p < 0.05, ##p < 0.01, ###p < 0.001, 5 × FAD young group (3–4 months old) vs. other 5 × FAD groups. *p < 0.05, **p < 0.01, ***p × 0.001, WT vs. 5 × FAD. (B) Representative western blot of TREM2 in whole hippocampal lysate, expressed as the mean ± S.E.M. (C) Representative confocal photomicrographs of the whole hippocampus. Note the increased immunoreactivity of TREM2 (red) in the hippocampus, especially in the CA1 region, of 5 × FAD mice. The expression increased with age. Scale bar = 200 μm. (D) Dual-label immunofluorescence image showing TREM2 (red) with microglia (green). Nuclei are stained with DAPI (blue). Notably, the increased immunoreactivity of TREM2 (red) was mostly associated with activated microglia (Iba1, green) rather than with resting microglia. Scale bar = 10 μm. (E) Immunohistochemistry (IHC) showing Aβ deposits stained with 6E10 in WT mice and 5 × FAD mice. Scale bar = 100 μm. (F) Dual-label immunofluorescence showing that TREM2 (red) is expressed mainly in plaque-associated areas (6E10, green). Scale bar = 10 μm. ns, not significant; TREM2, triggering receptor expressed on myeloid cells-2; WT, wild type; Iba1, ionized calcium-binding adapter molecule 1.
FIGURE 1 Elevated TREM2 protein and mRNA levels in activated microglia in the hippocampus of 5 × FAD mice during disease progression. (A) Analysis of the mRNA expression of TREM2 in the hippocampi of 1 month-old to 18–20 months-old 5 × FAD mice and aged-matched WT mice. The expression of TREM2 mRNA is presented as the mean ± S.E.M. and is shown as the relative expression level according to the 2Δ Δ Ct method. The data were analyzed via one-way analysis of variance followed by Bonferroni post hoc correction. #p < 0.05, ##p < 0.01, ###p < 0.001, 5 × FAD young group (3–4 months old) vs. other 5 × FAD groups. *p < 0.05, **p < 0.01, ***p × 0.001, WT vs. 5 × FAD. (B) Representative western blot of TREM2 in whole hippocampal lysate, expressed as the mean ± S.E.M. (C) Representative confocal photomicrographs of the whole hippocampus. Note the increased immunoreactivity of TREM2 (red) in the hippocampus, especially in the CA1 region, of 5 × FAD mice. The expression increased with age. Scale bar = 200 μm. (D) Dual-label immunofluorescence image showing TREM2 (red) with microglia (green). Nuclei are stained with DAPI (blue). Notably, the increased immunoreactivity of TREM2 (red) was mostly associated with activated microglia (Iba1, green) rather than with resting microglia. Scale bar = 10 μm. (E) Immunohistochemistry (IHC) showing Aβ deposits stained with 6E10 in WT mice and 5 × FAD mice. Scale bar = 100 μm. (F) Dual-label immunofluorescence showing that TREM2 (red) is expressed mainly in plaque-associated areas (6E10, green). Scale bar = 10 μm. ns, not significant; TREM2, triggering receptor expressed on myeloid cells-2; WT, wild type; Iba1, ionized calcium-binding adapter molecule 1.CC BY · PubMed Central
FIGURE 2 Upregulation of PU.1 protein and mRNA expression in the hippocampus of 5 × FAD mice during disease progression and triggering receptor expressed on myeloid cells-2 (TREM2) coexpression in microglia. (A). Single-label immunohistochemistry (IHC) for the transcription factor PU.1 alone in the hippocampi of Alzheimer’s disease (AD) and control mice. Scale bar = 100 μm. (B) Representative western blot of PU.1 in whole hippocampal lysate, expressed as the mean ± S.E.M. (C) Analysis of the mRNA expression of PU.1 in the hippocampus from 1 to 18–20 months-old 5 × FAD mice and aged-matched wild type (WT) mice. The expression of PU.1 is presented as the mean ± S.E.M. and is indicated as the relative expression level via the 2ΔΔCt method. The data were analyzed via one- or two-way analysis of variance followed by Bonferroni post hoc correction. #p < 0.05, ##p < 0.01, ###p < 0.001, 5 × FAD young group (3–4 months old) vs. the other 5 × FAD groups. *p < 0.05, **p < 0.01, ***p < 0.001, WT vs. 5 × FAD.
FIGURE 2 Upregulation of PU.1 protein and mRNA expression in the hippocampus of 5 × FAD mice during disease progression and triggering receptor expressed on myeloid cells-2 (TREM2) coexpression in microglia. (A). Single-label immunohistochemistry (IHC) for the transcription factor PU.1 alone in the hippocampi of Alzheimer’s disease (AD) and control mice. Scale bar = 100 μm. (B) Representative western blot of PU.1 in whole hippocampal lysate, expressed as the mean ± S.E.M. (C) Analysis of the mRNA expression of PU.1 in the hippocampus from 1 to 18–20 months-old 5 × FAD mice and aged-matched wild type (WT) mice. The expression of PU.1 is presented as the mean ± S.E.M. and is indicated as the relative expression level via the 2ΔΔCt method. The data were analyzed via one- or two-way analysis of variance followed by Bonferroni post hoc correction. #p < 0.05, ##p < 0.01, ###p < 0.001, 5 × FAD young group (3–4 months old) vs. the other 5 × FAD groups. *p < 0.05, **p < 0.01, ***p < 0.001, WT vs. 5 × FAD.CC BY · PubMed Central
FIGURE 3 The positive correlation between triggering receptor expressed on myeloid cells-2 (TREM2) gene expression and PU.1 in the microglia of 5 × FAD mice during chronic neurodegeneration. (A) A significant correlation was found between the mRNA and protein expression of TREM2 and that of PU.1 in 5 × FAD mice across the age groups. (B) Linear regression analysis revealed that total TREM2 protein levels in the hippocampus were positively correlated with PU.1 levels. *p < 0.05, **p < 0.01, ***p < 0.001. (C) Analysis of coexpression of TREM2 (red) and PU.1 (green) in the hippocampi of 5 × FAD mice and aged-matched wild type (WT) mice by double immunofluorescence. Scale bar = 20 μm.
FIGURE 3 The positive correlation between triggering receptor expressed on myeloid cells-2 (TREM2) gene expression and PU.1 in the microglia of 5 × FAD mice during chronic neurodegeneration. (A) A significant correlation was found between the mRNA and protein expression of TREM2 and that of PU.1 in 5 × FAD mice across the age groups. (B) Linear regression analysis revealed that total TREM2 protein levels in the hippocampus were positively correlated with PU.1 levels. *p < 0.05, **p < 0.01, ***p < 0.001. (C) Analysis of coexpression of TREM2 (red) and PU.1 (green) in the hippocampi of 5 × FAD mice and aged-matched wild type (WT) mice by double immunofluorescence. Scale bar = 20 μm.CC BY · PubMed Central
FIGURE 4 Aβ induced the upregulation of triggering receptor expressed on myeloid cells-2 (TREM2) and PU.1 expression in microglia in vitro. Treatment with 1 μM oAβ (A) or fAβ (B) was conducted for various durations in cultured BV-2 cells. (C,D) Representative single-label immunofluorescence staining of TREM2 in primary microglial cells after treatment with different doses of Aβ for 24 h. The values are expressed as the mean fluorescence intensity of TREM2. The data are expressed as relative fold changes compared with the controls. The values are expressed as the means ± S.E.M.s. Scale bar =10 μm. The data were analyzed via one-way analysis of variance followed by Bonferroni post hoc correction. (E) Quantitative real-time PCR analysis of TREM2 and PU.1 mRNA in primary microglia after 1 μM oAβ treatment at various time points. The expression of TREM2 is presented as the mean ± S.E.M. and is presented as the relative expression level according to the 2ΔΔCt method. The data were analyzed via one-way analysis of variance followed by Bonferroni post hoc correction. Aβ, amyloid beta. *p < 0.05, **p < 0.01, #p < 0.05, ##p < 0.01.
FIGURE 4 Aβ induced the upregulation of triggering receptor expressed on myeloid cells-2 (TREM2) and PU.1 expression in microglia in vitro. Treatment with 1 μM oAβ (A) or fAβ (B) was conducted for various durations in cultured BV-2 cells. (C,D) Representative single-label immunofluorescence staining of TREM2 in primary microglial cells after treatment with different doses of Aβ for 24 h. The values are expressed as the mean fluorescence intensity of TREM2. The data are expressed as relative fold changes compared with the controls. The values are expressed as the means ± S.E.M.s. Scale bar =10 μm. The data were analyzed via one-way analysis of variance followed by Bonferroni post hoc correction. (E) Quantitative real-time PCR analysis of TREM2 and PU.1 mRNA in primary microglia after 1 μM oAβ treatment at various time points. The expression of TREM2 is presented as the mean ± S.E.M. and is presented as the relative expression level according to the 2ΔΔCt method. The data were analyzed via one-way analysis of variance followed by Bonferroni post hoc correction. Aβ, amyloid beta. *p < 0.05, **p < 0.01, #p < 0.05, ##p < 0.01.CC BY · PubMed Central
FIGURE 5 PU.1 promotes triggering receptor expressed on myeloid cells-2 (TREM2) gene expression at the mRNA and protein levels. (A–D) The effects of lentiviral particles on TREM2 and PU.1 gene expression in BV2 cells were confirmed by western blotting and qRT–PCR. The protein level is expressed as the relative level in the untreated cells, while the mRNA level is presented as the mean ± S.E.M. and is indicated as the relative expression level according to the 2ΔΔCt method; *p < 0.05, **p < 0.01, ***p < 0.001, ##p < 0.01. The columns represent the results of the quantitative analysis of the expression of TREM2 and PU. (E) Immunofluorescence staining further revealed that PU.1 shRNA reduced the expression of TREM2 (red) and that the PU.1-overexpressing virus (PU.1 OE virus) increased the expression of TREM2. Scale bar = 10 μm. (F) The downregulation of TREM2 by PU.1 shRNA was also confirmed in primary microglia.Scale bar = 10 μm. EGFP = vector control. The values are expressed as the means ± S.E.M.s and were analyzed via ANOVA with Bonferroni post hoc correction. shRNA, short hairpin RNA.
FIGURE 5 PU.1 promotes triggering receptor expressed on myeloid cells-2 (TREM2) gene expression at the mRNA and protein levels. (A–D) The effects of lentiviral particles on TREM2 and PU.1 gene expression in BV2 cells were confirmed by western blotting and qRT–PCR. The protein level is expressed as the relative level in the untreated cells, while the mRNA level is presented as the mean ± S.E.M. and is indicated as the relative expression level according to the 2ΔΔCt method; *p < 0.05, **p < 0.01, ***p < 0.001, ##p < 0.01. The columns represent the results of the quantitative analysis of the expression of TREM2 and PU. (E) Immunofluorescence staining further revealed that PU.1 shRNA reduced the expression of TREM2 (red) and that the PU.1-overexpressing virus (PU.1 OE virus) increased the expression of TREM2. Scale bar = 10 μm. (F) The downregulation of TREM2 by PU.1 shRNA was also confirmed in primary microglia.Scale bar = 10 μm. EGFP = vector control. The values are expressed as the means ± S.E.M.s and were analyzed via ANOVA with Bonferroni post hoc correction. shRNA, short hairpin RNA.CC BY · PubMed Central
FIGURE 6 Direct binding between PU.1 and the triggering receptor expressed on myeloid cells-2 (TREM2) promoter or enhancer in vitro and in vivo and the regulation of the promoter activity of TREM2 The transcription factor PU.1 promoted TREM2 transcription. (A) Schematic representation of the TREM2 promoter sequence, which shows the sequences and positions of the four putative PU.1 binding sites highlighted in frame, used to study the binding site of the transcription factor PU.1 in the TREM2 promoter sequence. (B,C) A chromatin immunoprecipitation (ChIP) assay of microglial BV2 cells was performed using Abs against the PU.1 protein to immunoprecipitate chromatin from the cells. DNA fragments were analyzed by Quantitative real-time PCr (qRT–PCR) and are represented as percentages (%) input DNA (C); a PAGE gel graph (B) of the qRT–PCR results after the ChIP assay for different binding sites from (A) is shown. (D) The 3.0 kb DNA sequence upstream of the transcription start site (TSS) was cloned and inserted into the pGL4.1 basic vector. The TREM2 promoter plasmid or TREM2 promoter containing UTR fragment constructs were transfected alone or cotransfected with the PU.1 expression plasmid into HEK293 cells via Lipofectamine 3000, and the pRL-TK Renilla vector expression vector pRL-SV40 was used for normalization. After 48 h of transfection, luciferase activity was measured with a dual-luciferase reporter assay system. The data are expressed as the relative luciferase units (RLUs) of three separate experiments. ***p < 0.001.
FIGURE 6 Direct binding between PU.1 and the triggering receptor expressed on myeloid cells-2 (TREM2) promoter or enhancer in vitro and in vivo and the regulation of the promoter activity of TREM2 The transcription factor PU.1 promoted TREM2 transcription. (A) Schematic representation of the TREM2 promoter sequence, which shows the sequences and positions of the four putative PU.1 binding sites highlighted in frame, used to study the binding site of the transcription factor PU.1 in the TREM2 promoter sequence. (B,C) A chromatin immunoprecipitation (ChIP) assay of microglial BV2 cells was performed using Abs against the PU.1 protein to immunoprecipitate chromatin from the cells. DNA fragments were analyzed by Quantitative real-time PCr (qRT–PCR) and are represented as percentages (%) input DNA (C); a PAGE gel graph (B) of the qRT–PCR results after the ChIP assay for different binding sites from (A) is shown. (D) The 3.0 kb DNA sequence upstream of the transcription start site (TSS) was cloned and inserted into the pGL4.1 basic vector. The TREM2 promoter plasmid or TREM2 promoter containing UTR fragment constructs were transfected alone or cotransfected with the PU.1 expression plasmid into HEK293 cells via Lipofectamine 3000, and the pRL-TK Renilla vector expression vector pRL-SV40 was used for normalization. After 48 h of transfection, luciferase activity was measured with a dual-luciferase reporter assay system. The data are expressed as the relative luciferase units (RLUs) of three separate experiments. ***p < 0.001.CC BY · PubMed Central
FIGURE 7 PU.1-dependent Aβ-mediated triggering receptor expressed on myeloid cells-2 (TREM2) expression upregulation in microglia. Microglial BV2 cells were transduced with a lentiviral vector encoding PU.1 short hairpin RNA (shRNA) or PU.1 sequences or control virus. After treatment with different viruses, the cells were treated with 1 μM oAβ (A) or fAβ (B) for 24 h. (A,B) Representative western blot of TREM2 protein levels upon oAβ or fAβ stimulation. Loss of PU.1 abrogated Aβ-induced TREM2 upregulation in microglia.oAβ, oligomeric amyloid beta; f Aβ, fiber amyloid beta. *p < 0.05, **p < 0.01, ***p < 0.001, ##p < 0.01.
FIGURE 7 PU.1-dependent Aβ-mediated triggering receptor expressed on myeloid cells-2 (TREM2) expression upregulation in microglia. Microglial BV2 cells were transduced with a lentiviral vector encoding PU.1 short hairpin RNA (shRNA) or PU.1 sequences or control virus. After treatment with different viruses, the cells were treated with 1 μM oAβ (A) or fAβ (B) for 24 h. (A,B) Representative western blot of TREM2 protein levels upon oAβ or fAβ stimulation. Loss of PU.1 abrogated Aβ-induced TREM2 upregulation in microglia.oAβ, oligomeric amyloid beta; f Aβ, fiber amyloid beta. *p < 0.05, **p < 0.01, ***p < 0.001, ##p < 0.01.CC BY · PubMed Central
FIGURE 8 The impairment of microglial phagocytosis by triggering receptor expressed on myeloid cells-2 (TREM2) and PU.1 knockdown in vitro. (A) For the Aβ peptide phagocytosis assay, the cells were incubated alone with Hilyte-555-labeled fAβ (1–42) for 1 h (1.0 μM). After viral transduction, both TREM2 and PU.1 knockdown reduced microglial phagocytosis of fAβ (1–42). The mean fluorescence intensity (B) was quantified and is presented as the mean ± S.E.M. (C) For the microsphere phagocytosis assay, the cells were treated with Nile red microspheres (red) for 30 min. The cells were stained with phalloidin to visualize F-actin (green), and the percentages of microglia that underwent phagocytosis (C) and phagocytic efficiency (D) are presented as the means ± S.E.M.s (**p < 0.01). Scale bar = 10 μm. The data were quantified relative to those of the untreated group and analyzed via ANOVA with Bonferroni post hoc correction. *p < 0.05, ***p < 0.001, knockdown group versus control virus group.
FIGURE 8 The impairment of microglial phagocytosis by triggering receptor expressed on myeloid cells-2 (TREM2) and PU.1 knockdown in vitro. (A) For the Aβ peptide phagocytosis assay, the cells were incubated alone with Hilyte-555-labeled fAβ (1–42) for 1 h (1.0 μM). After viral transduction, both TREM2 and PU.1 knockdown reduced microglial phagocytosis of fAβ (1–42). The mean fluorescence intensity (B) was quantified and is presented as the mean ± S.E.M. (C) For the microsphere phagocytosis assay, the cells were treated with Nile red microspheres (red) for 30 min. The cells were stained with phalloidin to visualize F-actin (green), and the percentages of microglia that underwent phagocytosis (C) and phagocytic efficiency (D) are presented as the means ± S.E.M.s (**p < 0.01). Scale bar = 10 μm. The data were quantified relative to those of the untreated group and analyzed via ANOVA with Bonferroni post hoc correction. *p < 0.05, ***p < 0.001, knockdown group versus control virus group.CC BY · PubMed Central
FIGURE 9 Main schematic overview and working models used in this study.
FIGURE 9 Main schematic overview and working models used in this study.CC BY · PubMed Central

Verification

Claims the paper makes

13 Valid · 3 Not valid · 13 Not checked · 76 Own results and interpretations

54 more claims

Create a free account to see all 105 claims and to verify the 5 references still open.

See all claims — free account
  • Probably not a substantial claim. 22
  • It may state two separate claims as one. 30
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 69 references

Cited by

See all 7

Metadata

Authors
Wei, Z., Pan, X., Cui, X., Zhang, J., Dai, X., Zeng, Y., & Chen, X.
Affiliations
  • Fujian Medical University (CN)
  • Fujian University of Traditional Chinese Medicine (CN)
Corresponding author
  • Pan, Xiaodong
  • Chen, Xiaochun
Venue
Frontiers in Aging Neuroscience
Published
2025-05-01
Volume
17
Pages
1537388-1537388
ISSN
1663-4365 (ISSN-L)
OpenAlex
W4410014389
Cited by
7
References
69
Citations by year
2026: 5 · 2025: 2
FWCI
2.53
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Aging Neuroscience (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
Keywords
PU.1, TREM2, microglia, Alzheimer's disease, amyloid-beta, 5xFAD mice, microglial phagocytosis, microglial dysfunction, transcriptional regulation, therapeutic target

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PU.1 dictates β-amyloid-induced TREM2 expression upregulation in microglia in a transgenic model of Alzheimer’s disease. https://app.cochat.ai/papers/10.3389/fnagi.2025.1537388
The paper
Wei, Z., Pan, X., Cui, X., Zhang, J., Dai, X., Zeng, Y., & Chen, X. (2025). PU.1 dictates β-amyloid-induced TREM2 expression upregulation in microglia in a transgenic model of Alzheimer’s disease. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2025.1537388

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.